留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

人类免疫缺陷病毒感染者抗病毒治疗服药依从性监测与管理

马彩华 吕玮

马彩华, 吕玮. 人类免疫缺陷病毒感染者抗病毒治疗服药依从性监测与管理[J]. 协和医学杂志, 2019, 10(6): 627-632. doi: 10.3969/j.issn.1674-9081.2019.06.014
引用本文: 马彩华, 吕玮. 人类免疫缺陷病毒感染者抗病毒治疗服药依从性监测与管理[J]. 协和医学杂志, 2019, 10(6): 627-632. doi: 10.3969/j.issn.1674-9081.2019.06.014
Cai-hua MA, Wei LYU. Monitoring and Managing the Adherence to Antiretroviral Therapy in Patients with Human Immunodeficiency Virus Infection[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(6): 627-632. doi: 10.3969/j.issn.1674-9081.2019.06.014
Citation: Cai-hua MA, Wei LYU. Monitoring and Managing the Adherence to Antiretroviral Therapy in Patients with Human Immunodeficiency Virus Infection[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(6): 627-632. doi: 10.3969/j.issn.1674-9081.2019.06.014

人类免疫缺陷病毒感染者抗病毒治疗服药依从性监测与管理

doi: 10.3969/j.issn.1674-9081.2019.06.014
基金项目: 

"十三五"国家传染病重大专项 2017ZX10202102004

详细信息
    通讯作者:

    吕玮 电话:010-69155081, E-mail:lvweipumch@163.com

  • 中图分类号: R512.91

Monitoring and Managing the Adherence to Antiretroviral Therapy in Patients with Human Immunodeficiency Virus Infection

More Information
  • 摘要: 高效抗反转录病毒治疗大大降低了人类免疫缺陷病毒(human immunodeficiency virus, HIV)感染者的病死率, 使HIV感染者可获得长期存活。服药依从性是实现病毒抑制、延缓疾病进展的关键因素之一。目前依从性的测量方法可分为间接和直接测量两种。影响依从性的因素大致可分为个体水平因素、药物治疗方案因素、人际关系问题和结构性问题4大类。可提高依从性的方法有:短消息提醒、指导治疗及制定计划、实时依从性监测和应用长效抗病毒药物制剂等。虽然已有较多相关依从性的研究, 获得可推广的行之有效的依从性监测及提高手段仍存在较大挑战。
    利益冲突  无
  • [1] Viswanathan S, Justice AC, Alexander GC, et al.Adherence and HIV RNA Suppression in the Current Era of Highly Active Antiretroviral Therapy[J].J Acquir Immune Defic Syndr, 2015, 69:493-498. https://www.ncbi.nlm.nih.gov/pubmed/25886923
    [2] Ghidei L, Simone M, Salow M, et al. Aging, antiretro-virals, and adherence:a meta analysis of adherence among older HIV-infected individuals[J].Drugs Aging, 2013, 30:809-819.
    [3] Kanters S, Park JJ, Chan K, et al.Interventions to improve adherence to antiretroviral therapy:a systematic review and network meta-analysis[J].Lancet HIV, 2017, 4:e31-e40. http://www.sciencedirect.com/science/article/pii/S2352301816302065
    [4] Govindasamy D, Ford N, Kranzer K, et al. Risk factors, barriers and facilitators for linkage to antiretroviral therapy care:a systematic review[J]. AIDS, 2012, 26:2059-2067. http://europepmc.org/abstract/MED/22781227
    [5] Reuben RN, Spector AY, Mellins CA, et al.Optimizing ART adherence:update for HIV treatment and prevention[J].Curr HIV/AIDS Rep, 2014, 11:423-433. doi:  10.1007/s11904-014-0229-5
    [6] Layer EH, Kennedy CE, Beckham SW, et al. Multi-level factors affecting entry into and engagement in the HIV continuum of care in Iringa, Tanzania[J].PLoS One, 2014, 9:e104961. http://europepmc.org/articles/PMC4138017
    [7] Mudhune V, Gvetadze R, Girde S, et al.Correlation of Adherence by Pill Count, Self-report, MEMS and Plasma Drug Levels to Treatment Response Among Women Receiving ARV Therapy for PMTCT in Kenya[J].AIDS Behav, 2018, 22:918-928. doi:  10.1007/s10461-017-1724-7
    [8] Carter A, de Pokomandy A, Loutfy M, et al. Validating a self-report measure of HIV viral suppression:an analysis of linked questionnaire and clinical data from the Canadian HIV Women's Sexual and Reproductive Health Cohort Study[J]. BMC Res Notes, 2017, 10:138. https://www.ncbi.nlm.nih.gov/pubmed/28340606
    [9] Simoni JM, Kurth AE, Pearson CR, et al.Self-report measures of antiretroviral therapy adherence:A review with recommendations for HIV research and clinical management[J].AIDS Behav, 2006, 10:227-245. http://onlinelibrary.wiley.com/resolve/reference/PMED?id=16783535
    [10] Sewell J, Daskalopoulou M, Nakagawa F, et al. Accuracy of self-report of HIV viral load among people with HIV on antiretroviral treatment[J]. HIV Med, 2017, 18:463-473. doi:  10.1111/hiv.12477/abstract
    [11] Muñoz-Moreno JA, Fumaz CR, Ferrer MJ, et al.Assessing self-reported adherence to HIV therapy by questionnaire:the SERAD (Self-Reported Adherence) Study[J].AIDS Res Hum Retroviruses, 2007, 23:1166-1175. http://www.ncbi.nlm.nih.gov/pubmed/17961100/
    [12] Shirazi TN, Summers AC, Smith BR, et al. Concordance Between Self-Report and Performance-Based Measures of Everyday Functioning in HIV-Associated Neurocognitive Disorders[J]. AIDS Behav, 2017, 21:2124-2134. http://europepmc.org/abstract/med/28108876
    [13] Kagee A, Nel A.Assessing the association between self-report items for HIV pill adherence and biological measures[J].AIDS Care, 2012, 24:1448-1452. doi:  10.1080/09540121.2012.687816
    [14] Garrison LE, Haberer JE.Technological methods to measure adherence to antiretroviral therapy and preexposure prophylaxis[J].Curr Opin HIV AIDS, 2017, 12:467-474. http://www.ncbi.nlm.nih.gov/pubmed/28590335
    [15] Arnsten JH, Demas PA, Farzadegan H, et al.Antiretro-viral therapy adherence and viral suppression in HIV-infected drug users:Comparison of self-report and electronic monitoring[J]. Clin Infect Dis, 2001, 33:1417-1423.
    [16] Lampe FC.Sexual behaviour among people with HIV according to self-reported antiretroviral treatment and viral load status[J]. AIDS, 2016, 30:1745-1759. https://discovery.ucl.ac.uk/id/eprint/1480007/1/Lampe_Sexual%20behaviour%20among%20people%20with%20HIV%20according%20to%20self-reported%20antiretroviral%20treatment%20and%20viral%20load%20status.pdf
    [17] San Lio MM, Carbini R, Germano P, et al.Evaluating adherence to highly active antiretroviral therapy with use of pill counts and viral load measurement in the drug resources enhancement against AIDS and malnutrition program in Mozambique[J]. Clin Infect Dis, 2008, 46:1609-1616. http://www.ncbi.nlm.nih.gov/pubmed/18419498
    [18] Achieng L, Musangi H, Billingsley K, et al.The use of pill counts as a facilitator of adherence with antiretroviral therapy in resource limited settings[J].PLoS One, 2013, 8:e67259. http://www.ncbi.nlm.nih.gov/pubmed/24339861
    [19] Raymond JF, Bucek A, Dolezal C, et al. Use of Unannounced Telephone Pill Counts to Measure Medication Adherence Among Adolescents and Young Adults Living With Perinatal HIV Infection[J].J Pediatr Psychol, 2017, 42:1006-1015. http://academic.oup.com/jpepsy/article/42/9/1006/3092230
    [20] Okatch H, Beiter K, Eby J, et al.Brief Report:Apparent Antiretroviral Overadherence by Pill Count is Associated With HIV Treatment Failure in Adolescents[J].J Acquir Immune Defic Syndr, 2016, 72:542-545. http://smartsearch.nstl.gov.cn/paper_detail.html?id=c5a82541ee9166a71d32e7a85db69ff8
    [21] Misdrahi D, Tessier A, Husky M, et al.Evaluation of adherence patterns in schizophrenia using electronic monitoring (MEMS(R)):A six-month post-discharge prospective study[J].Schizophr Res, 2018, 193:114-118. https://www.ncbi.nlm.nih.gov/pubmed/28663027
    [22] Wagner GJ. Does discontinuing the use of pill boxes to facilitate electronic monitoring impede adherence?[J]. Int J STD AIDS, 2003, 14:64-65. http://www.ncbi.nlm.nih.gov/pubmed/12590799
    [23] Evans D, Berhanu R, Moyo F, et al.Can Short-Term Use of Electronic Patient Adherence Monitoring Devices Improve Adherence in Patients Failing Second-Line Antiretroviral Therapy? Evidence from a Pilot Study in Johannesburg, South Africa[J].AIDS Behav, 2016, 20:2717-2728. https://www.ncbi.nlm.nih.gov/pubmed/27146828
    [24] Baxi SM, Liu A, Bacchetti P, et al.Comparing the novel method of assessing PrEP adherence/exposure using hair samples to other pharmacologic and traditional measures[J]. J Acquir Immune Defic Syndr, 2015, 68:13-20. doi:  10.1097/qai.0000000000000386
    [25] Gandhi M, Ameli N, Bacchetti P, et al.Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy[J].Clin Infect Dis, 2011, 52:1267-1275. http://europepmc.org/articles/PMC3079399/
    [26] Hendrix CW, Andrade A, Bumpus NN, et al.Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066)[J].AIDS Res Hum Retroviruses, 2016, 32:32-43.
    [27] Hafezi H, Robertson TL, Au-Yeung K, et al.An inges-tible sensor for measuring medication adherence[J].IEEE Trans Biomed Eng, 2015, 62:99-109. http://www.ncbi.nlm.nih.gov/pubmed/25069107
    [28] Chai PR, Castillo-Mancilla J, Buffkin E, et al.Utilizing an Ingestible Biosensor to Assess Real-Time Medication Adherence[J].J Med Toxicol, 2015, 11:439-444. doi:  10.1007/s13181-015-0494-8
    [29] Mimiaga MJ, Bogart LM, Thurston IB, et al.Positive Strategies to Enhance Problem-Solving Skills (STEPS):A Pilot Randomized, Controlled Trial of a Multicomponent, Technology-Enhanced, Customizable Antiretroviral Adherence Intervention for HIV-Infected Adolescents and Young Adults[J]. AIDS Patient Care STDS, 2019, 33:21-24. http://www.ncbi.nlm.nih.gov/pubmed/30601059
    [30] Bachman DeSilva M, Gifford AL, Keyi X, et al.Feasibi-lity and Acceptability of a Real-Time Adherence Device among HIV-Positive IDU Patients in China[J].AIDS Res Treat, 2013, 2013:957862. https://core.ac.uk/display/99253953
    [31] Pop-Eleches C, Thirumurthy H, Habyarimana JP, et al.Mobile phone technologies improve adherence to antiretro-viral treatment in a resource-limited setting:a randomized controlled trial of text message reminders[J].AIDS, 2011, 25:825-834. doi:  10.1097/QAD.0b013e32834380c1
    [32] Duggal M, Chakrapani V, Liberti L, et al.Acceptability of Mobile Phone-Based Nurse-Delivered Counseling Intervention to Improve HIV Treatment Adherence and Self-Care Behaviors Among HIV-Positive Women in India[J].AIDS Patient Care STDS, 2018, 32:349-359. doi:  10.1089/apc.2017.0315
    [33] Quintana Y, Gonzalez Martorell EA, Fahy D, et al.A Systematic Review on Promoting Adherence to Antiretroviral Therapy in HIV-infected Patients Using Mobile Phone Technology[J].Appl Clin Inform, 2018, 9:450-466. https://www.ncbi.nlm.nih.gov/pubmed/29925099
    [34] Lyon ME, Trexler C, Akpan-Townsend C, et al.A family group approach to increasing adherence to therapy in HIV-infected youths:results of a pilot project[J].AIDS Patient Care STDS, 2003, 17:299-308. doi:  10.1089/108729103322108175
    [35] Franke M, Murray M, Muñoz M, et al. Food insufficiency is a risk factor for suboptimal antiretroviral therapy adherence among HIV-infected adults in urban Peru[J]. AIDS Behav, 2011, 15:1483-1489. doi:  10.1007/s10461-010-9789-6
    [36] Deribe K, Hailekiros F, Biadgilign S, et al. Defaulters from antiretroviral treatment in Jimma University Specialized Hospital, Southwest Ethiopia[J]. Trop Med Int Health, 2008, 13:328-333. doi:  10.1111/j.1365-3156.2008.02006.x
    [37] Martinez H, Palar K, Linnemayr S, et al.Tailored nutrition education and food assistance improve adherence to HIV antiretroviral therapy:evidence from Honduras[J].AIDS Behav, 2014, 18:S566-S577. doi:  10.1007/s10461-014-0786-z
    [38] Haberer JE, Kahane J, Kigozi I, et al.Real-time adher-ence monitoring for HIV antiretroviral therapy[J].AIDS Behav, 2010, 14:1340-1346. doi:  10.1007/s10461-010-9799-4
    [39] de Sumari-de Boer IM, van den Boogaard J, Ngowi KM, et al. Feasibility of real time medication monitoring among HIV infected and TB patients in a resource-limited setting[J]. AIDS Behav, 2016, 20:1097-1107. doi:  10.1007/s10461-015-1254-0
    [40] Castillo-Mancilla JR, Haberer JE.Adherence Measurements in HIV:New Advancements in Pharmacologic Methods and Real-Time Monitoring[J]. Curr HIV/AIDS Rep, 2018, 15:49-59. doi:  10.1007/s11904-018-0377-0
    [41] Stailey M, Conway SE, et al.Review of the Next Generation of Long-Acting Basal Insulins:Insulin Degludec and Insulin Glargine[J].Consult Pharm, 2017, 32:42-46. http://www.ncbi.nlm.nih.gov/pubmed/28077204
    [42] McGowan I, Dezzutti CS, Siegel A, et al. Long-acting rilpivirine as potential preexposure prophylaxis for HIV-1 prevention (the MWRI-01 study):an openlabel, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment[J]. Lancet HIV, 2016, 3:e569-e578. doi:  10.1016/S2352-3018(16)30113-8
    [43] Ferretti F, Boffito M.Rilpivirine long-acting for the prevention and treatment of HIV infection[J].Curr Opin HIV AIDS, 2018, 13:300-307. http://www.ncbi.nlm.nih.gov/pubmed/29794818
  • 加载中
计量
  • 文章访问数:  304
  • HTML全文浏览量:  17
  • PDF下载量:  157
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-02-19
  • 刊出日期:  2019-11-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!